Magnetic fucoidan-based nanoparticles conjugated with T-cell activators and checkpoint inhibitors can be directed to tumours via magnetic navigation for improving therapeutic efficacy and reducing systemic side effects.
- Chih-Sheng Chiang
- Yu-Jung Lin
- San-Yuan Chen